UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000014107 |
|---|---|
| Receipt number | R000016421 |
| Scientific Title | A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer |
| Date of disclosure of the study information | 2014/05/29 |
| Last modified on | 2019/10/02 16:13:42 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2014/05/29 14:23:34 | ||
| 2 | Update | 2014/12/01 16:04:48 | Key inclusion criteria |
|
| 3 | Update | 2019/10/02 16:13:42 | Recruitment status Date of IRB |
